Beneficial Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Asthma: A Literature Review

Kanwar, Meeta K; Sunku, Ramya; Alruwaili, Faisal; Mufti, Mariam A; Raji, Mukaila

doi:10.7759/cureus.30812

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GLP-1 acts through the activation of G-protein-coupled receptors. GLP-1R and GLP-1R agonists are already approved for type-2 diabetes mellitus (T2DM) and obesity treatment [ 193 ]. The early research has demonstrated that the level of plasma GLP-1 after oral carbohydrate ingestion is considerably decreased in obese patients in comparison to a lean group [ 194 ].…”

Section: Peptides In Asthma–obesity Phenotypementioning

confidence: 99%

“…GLP-1, in addition to participating in glycemic control, has anti-inflammatory properties under many different conditions [ 195 ]. Given the fact that GLP-1R receptors are present in the respiratory tract, including airway smooth muscle cells, pulmonary vasculature, or type-II alveolar cells [ 193 ], GLP-1 may play an important role in the inflammatory processes associated with asthma. In fact, in a murine model of OVA-induced asthma, GLP-1 analog liraglutide significantly reduced airway inflammation, mucus hypersecretion, and elevated levels of E-selectin or MUC5AC mucin [ 196 ], whereas another GLP-1R agonist, exendin-4, showed a bronchorelaxant effect, alleviating hyperresponsiveness of human isolated bronchi subjected to passive sensitization and high-glucose concentration [ 197 ].…”

Section: Peptides In Asthma–obesity Phenotypementioning

confidence: 99%

See 1 more Smart Citation

The Role of Peptides in Asthma–Obesity Phenotype

Russjan

2024

IJMS

View full text Add to dashboard Cite

The co-occurrence of asthma and obesity is becoming an increasingly common health problem. It became clear that both diseases are closely related, since overweight/obesity are associated with an increased risk of asthma development, and more than half of the subjects with severe or difficult-to-treat asthma are obese. Currently, there are no specific guidelines for the treatment of this group of patients. The mechanisms involved in the asthma–obesity phenotype include low-grade chronic inflammation and changes in pulmonary physiology. However, genetic predispositions, gender differences, comorbid conditions, and gut microbiota also seem to be important. Regulatory peptides affect many processes related to the functioning of the respiratory tract and adipose tissue. Adipokines such as leptin, adiponectin, resistin, and the less studied omentin, chemerin, and visfatin, as well as the gastrointestinal hormones ghrelin, cholecystokinin, glucagon-like peptide-1, and neuropeptides, including substance P or neuropeptide Y, can play a significant role in asthma with obesity. The aim of this article is to provide a concise review of the contribution of particular peptides in inflammatory reactions, obesity, asthma, and a combination of both diseases, as well as emphasize their potential role in the effective treatment of the asthma–obesity phenotype in the future.

show abstract

Section: Peptides In Asthma–obesity Phenotypementioning

confidence: 99%